![Brian S. G. Fielding](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Brian S. G. Fielding
Direttore Finanziario/CFO presso Cita NeuroPharmaceuticals, Inc.
Profilo
Brian S.
G.
Fielding is currently the Chief Financial Officer at Cita NeuroPharmaceuticals, Inc. He previously served as the Chief Executive Officer at Millenium Biologix Corp.
in 2006-2007, and as the Chief Financial Officer at GLYCODesign, Inc. He also served as the Chief Operating & Financial Officer at PharmEng International, Inc. in 2008-2009.
Mr. Fielding received his undergraduate degree from the University of Toronto.
Posizioni attive di Brian S. G. Fielding
Società | Posizione | Inizio |
---|---|---|
Cita NeuroPharmaceuticals, Inc.
![]() Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Direttore Finanziario/CFO | - |
Precedenti posizioni note di Brian S. G. Fielding
Società | Posizione | Fine |
---|---|---|
PharmEng International, Inc.
![]() PharmEng International, Inc. Miscellaneous Commercial ServicesCommercial Services PharmEng International, Inc. was a full-service consulting and contract manufacturing company, which serves the pharmaceutical and biotechnology industries. The company was founded on October 1, 2003 and was headquartered in Markham, ON. | Direttore Finanziario/CFO | 14/04/2009 |
Millenium Biologix Corp.
![]() Millenium Biologix Corp. BiotechnologyHealth Technology Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON. | Presidente | 08/05/2007 |
GLYCODesign, Inc.
![]() GLYCODesign, Inc. Pharmaceuticals: MajorHealth Technology GLYCODesign, Inc. develops pharmaceutical products. The company engages in the discovery and development of novel therapeutics for life-threatening diseases such as cancer, infectious diseases, inflammation, and cardiovascular diseases. GLYCODesign focuses on inhibiting the enzymes that produce the abnormal carbohydrates. The company was founded by Jeremy Carver in 1993 and is headquartered in Toronto, Canada. | Direttore Finanziario/CFO | - |
Formazione di Brian S. G. Fielding
University of Toronto | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
GLYCODesign, Inc.
![]() GLYCODesign, Inc. Pharmaceuticals: MajorHealth Technology GLYCODesign, Inc. develops pharmaceutical products. The company engages in the discovery and development of novel therapeutics for life-threatening diseases such as cancer, infectious diseases, inflammation, and cardiovascular diseases. GLYCODesign focuses on inhibiting the enzymes that produce the abnormal carbohydrates. The company was founded by Jeremy Carver in 1993 and is headquartered in Toronto, Canada. | Health Technology |
Millenium Biologix Corp.
![]() Millenium Biologix Corp. BiotechnologyHealth Technology Millenium Biologix Corp. is focused on the development and commercialization of next generation, skeletal tissue regeneration products and implantable medical devices, initially targeted for orthopedic uses. These products, used alone or in combination configurations, promote the repair and natural healing of human bone and other skeletal tissues such as cartilage. Millenium's strength in developing leading treatments for regenerative medicine is based on its successful integration of three core competencies in advanced biomaterials, biologics and engineering. Its core business activities are focused on tissue engineering products, and on orthobiologicals. It was founded on April 1, 1998 and is headquartered in Kingston, ON. | Health Technology |
Cita NeuroPharmaceuticals, Inc.
![]() Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cita Neuro Pharmaceuticals, Inc. develops and commercializes small molecule drugs. Its clinical drug portfolio consists of drugs for Parkinson's disease and neuropathic pain. Cita Neuro Pharmaceuticals was founded in 1997 by Brian Bennett, Roland Boegman, Khem Jha-mandas, James Reynolds and Gregory Thatcher and is headquartered in Mississauga, Canada. | Health Technology |
PharmEng International, Inc.
![]() PharmEng International, Inc. Miscellaneous Commercial ServicesCommercial Services PharmEng International, Inc. was a full-service consulting and contract manufacturing company, which serves the pharmaceutical and biotechnology industries. The company was founded on October 1, 2003 and was headquartered in Markham, ON. | Commercial Services |
- Borsa valori
- Insiders
- Brian S. G. Fielding